Gen-probe, Inc.

Grifols Diagnostic Solutions Inc.

Jeffrey M Linnen

Kui Gao

Reinhold B Pollner

Wen Wu

Jijumon Chelliserry

Michael McClellan Becker

Damon Kittredge Getman

Edgar Ong

Daniel Kolk

James M Carrick

Janel M Dockter

Leslie A Stringfellow

Jennifer Cole

Tadashi Yoshimura

Martha K Ho-Sing-Loy

Paul M Darby

Patricia C Gordon

Vanessa Bres

Tan N Le

Kurt Craft Norton

Deanna Self

Dat Do

Geoffrey G Dennis

Reinhold P Pollner

Edgar O Ong

Daniel P Kolk

There is described herein a method for specifically detectingspecies nucleic acid in a sample, which in one aspect comprises: (1) contacting a sample, said sample suspected of containingspecies nucleic acid, with at least two oligomers for amplifying a target region of aspecies target nucleic acid, wherein the at least two amplification oligomers comprise: (a) a first amplification oligomer comprising a first target-hybridizing sequence (i) that is from about 15 to about 33 contiguous nucleotides in length, is contained in the sequence of SEQ ID NO:66 and comprises SEQ ID NO:56 or 57; or (ii) that is from about 15 to about 33 contiguous nucleotides in length, is contained in the sequence of SEQ ID NO:96 and comprises SEQ ID NO:101; or (iii) that is from about 15 to about 33 contiguous nucleotides in length, is contained in the sequence of SEQ ID NO:97 and comprises SEQ ID NO:101; (iv) comprises or consists of SEQ ID NO:8; (v) comprises or consists of SEQ ID NO:83 and (b) a second amplification oligomer comprising a second target-hybridizing sequence that is from about 15 to about 33 contiguous nucleotides in length, and (i) is contained in SEQ ID NO:68 and comprises SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, or SEQ ID NO:85; or (ii) is contained in SEQ ID NO:67 and comprises SEQ ID NO:45 or SEQ ID NO:52; or (iii) is contained in SEQ ID NO:70 and comprises SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, or SEQ ID NO:51; (2) performing an in vitro nucleic acid amplification reaction, wherein anytarget nucleic acid present in said sample is used as a template for generating an amplification product; and (3) detecting the presence or absence of the amplification product, thereby indicating the presence or absence ofspecies target nucleic acid in said sample.

Detectingspecies nucleic acid in a sample

Compositions, methods and kits for detecting Chikungunya virus (CHIKV) nucleic acids are for detecting very low levels of the viral nucleic acids using nucleic acid amplification. The kit includes a first primer up to 100 bases long and includes a target-complementary 3' terminal sequence of 15-48 contiguous bases. The first primer optionally may include a first primer 5′ sequence (i.e., an upstream sequence) that is not complementary to CHIKV nucleic acids.

Method for detecting Chikungunya virus

Disclosed herein are lysis reagents for lysing red blood cells, thereby releasing an analyte, such as RNA from a host or pathogen, in a form suitable for analysis. The reagent includes at least a buffer, a detergent and one or both of a chloride containing salt and an anti-coagulant. The reagent serves to lyse blood cells, protect the released analyte from degradation in the lysate, and is compatible with subsequent steps for analysis of the analyte such as target capture, amplification, detection, or sequencing.

Blood cell lysis reagent

Disclosed are nucleic acid oligomers, including amplification oligomers, capture probes, and detection probes, for detection of Zika virus nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding reaction mixtures and kits.

Compositions and methods for detecting Zika virus nucleic acid

Disclosed are nucleic acid oligomers, including amplification oligomers, capture probes, and detection probes, for detection of Hepatitis E Virus (HEV) nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding reaction mixtures and kits.

Compositions and methods for detecting HEV nucleic acid

Nucleic acid oligomers specific for human parvovirus genomic DNA are disclosed. An assay for amplifying and detecting human parvovirus genotypes 1, 2 and 3 nucleic acid in biological specimens is disclosed. Compositions for amplifying and detecting the presence of human parvovirus genotypes 1, 2 and 3 genomic DNA in human biological specimens are disclosed.

Compositions and method for detecting hepatitis a virus nucleic acids in single-plex or multiplex assays

Various aspects of the invention relate to compositions and methods of analyzing blood plasma, blood serum, and manufacturing pools of plasma-derived products wherein an anionic surfactant is added to an aliquot of the blood plasma, blood serum, or manufacturing pool prior to analysis, and the counterion of the anionic surfactant is not sodium ion. The anionic surfactant may be, for example, lauryl sulfate. The counterion of the anionic surfactant may be, for example, lithium ion.

Method to homogenize parvovirus B19 in clinical samples

This disclosure provides oligomers, compositions, and kits for detecting and quantifying Hepatitis B virus (HBV), including different genotypes and variants thereof, and related methods and uses. In some embodiments, oligomers target the P and/or S open reading frames of HBV and are configured to provide substantially equivalent quantification of different genotypes and variants of HBV.

Compositions and methods for detecting or quantifying Hepatitis B virus

The invention provides a lysis reagent for lysing red blood cells, thereby releasing a target, such as RNA from a parasitic organism, in a form suitable for analysis. The reagent includes at least ammonium chloride and an anionic detergent, and may include an anti-coagulant. The reagent serves to lyse red blood cells, protect the released target from degradation in the lysate, and is compatible with subsequent steps for analysis of the target such as target capture, amplification, detection, or sequencing.

Methods for isolating a target nucleic acid from red blood cells

Compositions for detectingnucleic acids. Particularly described are compositions for detecting West Nile virus nucleic acids in the 3' non-coding region. These compositions are preferably oligonucleotides comprising nucleotide sequences that are substantially complementary to a West Nile virus target nucleic acid. These compositions preferably comprise a detectable moiety.

Growing community of inventors

Poway, CA, United States of America

Jeffrey M Linnen